Tags

Type your tag names separated by a space and hit enter

Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure.
J Card Fail. 2003 Aug; 9(4):318-24.JC

Abstract

BACKGROUND

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide, and patients with chronic heart failure (CHF) are reported to have high plasma ET-1 levels. The aim of this study was to investigate the relation between plasma ET-1 levels and clinical correlates in patients with CHF. The effects of maximal exercise on plasma ET-1 levels were also investigated.

METHODS

Plasma concentrations of ET-1, norepinephrine, and atrial and brain natriuretic peptide (ANP and BNP) both at rest and after maximal cardiopulmonary exercise test were determined in 100 patients with CHF (60 +/- 12 years, New York Heart Association [NYHA] class I-III, left ventricular ejection fraction [LVEF]=36 +/- 8%, peak oxygen uptake [VO2] = 18.2 +/- 5.0 mL/min/kg) and 27 controls.

RESULTS

Patients with NYHA class II and III CHF had higher ET-1 levels (controls, NYHA class I, II, III: 2.1 +/- 0.6, 2.1 +/- 1.0, 2.6 +/- 0.9, 3.4 +/- 0.8 pg/mL, analysis of variance P <.0001). Maximal exercise did not alter ET-1 levels in controls or in each CHF subgroup. When all CHF patients were analyzed together, cardiothoracic ratio (P<.01), peak VO2 (P<.001), plasma norepinephrine (P<.01), plasma ANP (P<.01), and plasma BNP (P<.001) were significantly related with resting ET-1 levels on univariate analysis. Multivariate analysis revealed peak VO2 and plasma BNP levels showed an independent and significant relationship with the resting plasma ET-1 levels.

CONCLUSIONS

Resting ET-1 levels were increased in symptomatic patients with CHF, and maximal exercise did not increase ET-1 levels. Peak VO2 and plasma BNP levels were independently associated with resting plasma ET-1 levels in patients with CHF.

Authors+Show Affiliations

Department of Cardiovascular Medicine, Tottori University Faculty of Medicine, Yonago, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article

Language

eng

PubMed ID

13680553

Citation

Kinugawa, Toru, et al. "Plasma Endothelin-1 Levels and Clinical Correlates in Patients With Chronic Heart Failure." Journal of Cardiac Failure, vol. 9, no. 4, 2003, pp. 318-24.
Kinugawa T, Kato M, Ogino K, et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail. 2003;9(4):318-24.
Kinugawa, T., Kato, M., Ogino, K., Osaki, S., Igawa, O., Hisatome, I., & Shigemasa, C. (2003). Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. Journal of Cardiac Failure, 9(4), 318-24.
Kinugawa T, et al. Plasma Endothelin-1 Levels and Clinical Correlates in Patients With Chronic Heart Failure. J Card Fail. 2003;9(4):318-24. PubMed PMID: 13680553.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. AU - Kinugawa,Toru, AU - Kato,Masahiko, AU - Ogino,Kazuhide, AU - Osaki,Shuichi, AU - Igawa,Osamu, AU - Hisatome,Ichiro, AU - Shigemasa,Chiaki, PY - 2003/9/19/pubmed PY - 2004/3/20/medline PY - 2003/9/19/entrez SP - 318 EP - 24 JF - Journal of cardiac failure JO - J Card Fail VL - 9 IS - 4 N2 - BACKGROUND: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide, and patients with chronic heart failure (CHF) are reported to have high plasma ET-1 levels. The aim of this study was to investigate the relation between plasma ET-1 levels and clinical correlates in patients with CHF. The effects of maximal exercise on plasma ET-1 levels were also investigated. METHODS: Plasma concentrations of ET-1, norepinephrine, and atrial and brain natriuretic peptide (ANP and BNP) both at rest and after maximal cardiopulmonary exercise test were determined in 100 patients with CHF (60 +/- 12 years, New York Heart Association [NYHA] class I-III, left ventricular ejection fraction [LVEF]=36 +/- 8%, peak oxygen uptake [VO2] = 18.2 +/- 5.0 mL/min/kg) and 27 controls. RESULTS: Patients with NYHA class II and III CHF had higher ET-1 levels (controls, NYHA class I, II, III: 2.1 +/- 0.6, 2.1 +/- 1.0, 2.6 +/- 0.9, 3.4 +/- 0.8 pg/mL, analysis of variance P <.0001). Maximal exercise did not alter ET-1 levels in controls or in each CHF subgroup. When all CHF patients were analyzed together, cardiothoracic ratio (P<.01), peak VO2 (P<.001), plasma norepinephrine (P<.01), plasma ANP (P<.01), and plasma BNP (P<.001) were significantly related with resting ET-1 levels on univariate analysis. Multivariate analysis revealed peak VO2 and plasma BNP levels showed an independent and significant relationship with the resting plasma ET-1 levels. CONCLUSIONS: Resting ET-1 levels were increased in symptomatic patients with CHF, and maximal exercise did not increase ET-1 levels. Peak VO2 and plasma BNP levels were independently associated with resting plasma ET-1 levels in patients with CHF. SN - 1071-9164 UR - https://www.unboundmedicine.com/medline/citation/13680553/Plasma_endothelin_1_levels_and_clinical_correlates_in_patients_with_chronic_heart_failure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S107191640300054X DB - PRIME DP - Unbound Medicine ER -